Compare SAP SE (SAP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs State Street SPDR S&P Biotech ETF — how do they compare? SAP SE trades at $202.84 (market cap $240.81B), while State Street SPDR S&P Biotech ETF trades at $159.21. The key difference: SAP SE pays a 1.4% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SAP SE nearer its low. Which is the better fit depends on your goals.
| SAP | XBI | |
|---|---|---|
Market Cap | $240.81B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $280.46 | $164.28 |
52-Week Low | $146.38 | $86.92 |
Enterprise Value | $239.52B | — |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP stock trades at $203.07, down 2.63% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong Q2 2026 revenue growth driven by cloud demand, though it missed EPS estimates. Fundamentals show robust profitability with a 20.41% net income margin and rising cash flow from operations to $9.16B in 2025. Recent news highlights AI and cloud strategy advancements, with shares reacting positively to analyst upgrades and earnings resilience.
The outlook is cautiously optimistic, with a consensus price target of $209.67 offering modest upside. Investment opportunities lie in SAP's cloud transition and AI integration, but risks include execution challenges, margin pressure from investments, and competitive threats. The stock's valuation at a P/E of 27.16 may limit near-term gains if growth slows.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
